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A B S T R A C T
Aim: CYP2C19 polymorphism modulates platelet reactivity in coronary artery disease patients with
stent implants. However, the impact of the CYP2C19 genotype on clopidogrel response and clinical
outcome has not been fully understood to date.
Methods: We enrolled 518 consecutive patients with acute coronary syndrome (ACS) (n = 214) and
stable angina (SA) (n = 304). All patients received stent implants followed by dual antiplatelet therapy of
aspirin and clopidogrel. We determined CYP2C19 phenotype, measured platelet reactivity, and assessed
the risk of cardiovascular events.
Results: During a median follow-up of 894 days, the rate of cardiovascular events was higher in patients
of the ACS group than the SA group (ACS: 20.1%, SA: 12.5%, p = 0.015). The mean platelet reactivity was
signiﬁcantly higher in the CYP2C19 loss-of-function allele carriers of the two groups (ACS, non-carriers:
3909  1836 AU min, carriers: 4854  1594 AU min, respectively, p < 0.01; SA, 3606  1579 AU min,
4381  1373 AU min, SD, p < 0.01). In the ACS group, cardiovascular events were higher in the loss-of-
function allele carriers (24.6%) versus non-carriers (11.1%, p < 0.05), but no such difference was noted in the
SA group (carriers: 14.8%; non-carriers: 7.9%, p = 0.078). Furthermore, landmark analysis from 30 days did
not show differences in ACS group (carriers: 14.8%, non-carriers: 11.1%, p = 0.315). Multivariate Cox
proportional hazards analysis identiﬁed the presence of loss-of-function allele as an independent predictor of
cardiovascular events (hazard ratio, 2.1, 95% CI, 1.194–3.587, p = 0.010).
Conclusions: The impact of CYP2C19 loss-of-function gene on clinical outcome is more powerful in early
phase of ACS compared with SA.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Dual antiplatelet therapy with aspirin and thienopyridine
reduces the risk of stent thrombosis after stent implantation [1–3].
Clopidogrel is the mainstay drug for the dual antiplatelet therapy;
however, some patients do not achieve adequate antiplatelet
effect [4,5]. Cytochrome P450 2C19 enzyme (CYP2C19) converts
clopidogrel to an active metabolite [6,7], and the presence of
CYP2C19 loss-of-function alleles is associated with reduced* Corresponding author at: Department of Cardiovascular Medicine, Graduate
School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku,
Kumamoto 860-8556, Japan. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail address: shokimot@kumamoto-u.ac.jp (S. Hokimoto).
http://dx.doi.org/10.1016/j.jjcc.2014.07.016
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsclopidogrel responsiveness in patients with coronary heart disease
(CHD) [8].
The prevalence of CYP2C19 loss-of-function alleles is different
in each racial group. For example, the rate is relatively higher in
East Asians, including Japanese, compared with Caucasians [9,10].
We reported previously the prevalence of CYP2C19 loss-of-
function alleles among Japanese patients with CHD and its relation
to residual platelet reactivity [11]. The study identiﬁed carriers
with at least one of the CYP2C19 loss-of-function alleles who
showed higher residual platelet reactivity compared to non-
carriers with stable angina (SA) status.
High residual platelet reactivity status is known as a risk factor
for ischemic events after percutaneous coronary intervention (PCI)
[12], and some studies reported a close relation between presence
of CYP2C19 reduced-function allele and adverse cardiovascular reserved.
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CYP2C19 loss-of-function alleles has not been fully elucidated
[15,16]. In addition, most subjects of previous studies on this issue
were Caucasians, i.e. different genetic background from Japanese.
Furthermore, in our previous study, we only assessed patients with
stable CHD, but not those with acute coronary syndrome (ACS).
Based on this background, the present study was designed to
determine the impact of CYP2C19 polymorphism on the response
to clopidogrel and also to compare the clinical outcome of Japanese
patients with ACS and SA.
Methods
Study population
The study subjects were 518 patients representing 214
consecutive patients with ACS and 304 consecutive patients with
SA, who were admitted to our hospital between June 2008 and May
2012. The deﬁnition of ACS and SA was guideline-based [17–19].
All patients underwent cardiac catheterization and PCI during
hospitalization. All subjects were being treated with maintenance
doses of 100 mg/day aspirin and 75 mg/day clopidogrel after a
loading dose of 300 mg clopidogrel. This study is a prospective
single center study, with a mean follow-up period of 909 days
(median: 893 days, maximum: 1800 days). The study protocol was
approved by the ethics committee of the hospital and written
informed consent was obtained from the patients or their families
(the approval number: 64).
Genotyping
Genomic DNA was extracted from whole blood using a DNA
Extractor WB kit (Wako Pure Chemical Industries, Osaka, Japan)
using the modiﬁed protocol described by Richards et al. [20].
Polymerase chain reaction–restriction fragment length polymor-
phisms for CYP2C19*2 (681G>A) and CYP2C19*3 (636G>A) was
performed as described previously [21]. CYP2C19*2 and *3 are
considered to account for >99% of the alleles generating the null-
activity enzyme protein in the Japanese population [21]. Therefore,
the subjects were divided according to the CYP2C19 genotypes into
three phenotypes: (1) extensive metabolizers (EM) carrying
normal function alleles (CYP2C19*1/*1); (2) intermediate meta-
bolizers (IM) carrying one loss-of-function allele (*1/*2, *1/*3); and
(3) poor metabolizers (PM) carrying two loss-of-function alleles
(*2/*2, *2/*3, *3/*3). In this study, we deﬁned carriers as those
subjects who held at least one loss-of-function allele and non-
carriers as those who carried homozygous normal function alleles.
Measurement of residual platelet reactivity
Platelet reactivity was measured the next day after clopidogrel
loading and ﬁrst maintenance dose administration for elective PCI.
It has been reported that platelet reactivity does not change
signiﬁcantly from day 3 to 6 in patients with ST-elevation
myocardial infarction who undergo PCI [11]. Therefore, platelet
function test was performed 3 days after stent implantation for
emergent PCI. Platelet aggregation was measured as follows. Blood
samples were withdrawn into glass tubes containing 0.38% sodium
citrate solution. Platelet-rich plasma was prepared by centrifuga-
tion at 3000 rpm at room temperature for 15 min, followed by
centrifugation at 3000 rpm at room temperature for 10 min, in
order to separate platelet-poor plasma. Aggregation in platelet-
rich plasma induced by 20 mmol/L adenosine diphosphate (ADP;
Chrono-Log, Havertown, PA, USA) was measured using a light
transmission aggregometer (MCM HEMA TRACER 313; PAM12C,
LMS Inc., Tokyo, Japan), where the degree of light transmission ofplatelet-rich plasma was deﬁned as 0% of the aggregation rate, and
the cognitive platelet-poor plasma as 100%. Test time was 10 min.
Residual platelet reactivity was deﬁned as the area under the
platelet aggregation curve, which was used to express the
aggregation response over the measured time (aggregation units
min, AU min) [22,23].
We used on-treatment platelet reactivity directly, rather than
inhibition of platelet aggregation calculated as percent decrease in
the relative maximal platelet aggregation from baseline. This
approach was based on studies that have shown that assessment of
clopidogrel response that depends on baseline platelet reactivity is
a less reliable predictor of ischemic risk than post-treatment
platelet reactivity [5,24]. The area under the aggregation curve
(AU min) is more sensitive and precise than maximal platelet
aggregation calculated from the percentage of inhibition [11].
Accordingly, we used the area under the aggregation curve as a
measure of on-treatment platelet reactivity during antiplatelet
therapy.
Clinical outcomes
The study endpoints were residual platelet reactivity and
cardiovascular death, nonfatal myocardial infarction, ischemic
stroke, unstable angina, any urgent revascularization, or intra-
procedural thrombotic events (IPTE). Revascularization therapy
based only on angiographic data and urgent revascularization was
deﬁned as emergent revascularization for unexpected hospitaliza-
tion. IPTE was deﬁned as the development of new or increasing
thrombus, abrupt complete vessel obstruction, no reﬂow, slow
reﬂow, or distal embolism at any time during the procedure. We
examined patients once every month after discharge and
performed a follow-up angiography at 6–9 months after the
procedure. Then, the patients were followed every 6 months in the
outpatient department after the re-study and contacted by
telephone calls to subjects (or their families) in the absence of
hospital visits. Cardiovascular death was deﬁned as death due to
myocardial infarction, congestive heart failure, or documented
sudden cardiac death. We used the universal deﬁnition of
myocardial infarction in this study [25]. The diagnosis of stroke
was based on clinical and radiological evidence of stroke. For
subjects experiencing more than two acute events, only the ﬁrst
event was considered in the analysis. See also Supplemental
Table 1.
Supplementary Table 1 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jjcc.2014.07.016.
Statistical analysis
We stratiﬁed platelet reactivity and clinical outcome according
to the clinical status and the presence/absence of loss-of-function
allele. Continuous variables were expressed as mean  SD, while
categorical variables were expressed as frequencies and percentages.
Statistical analyses were performed exclusively by an independent
statistician. The baseline characteristics according to the clinical
status and CYP2C19 phenotype were compared using the x2-test for
categorical variables, and Student’s t-test for continuous variables, as
appropriate. The time to ﬁrst cardiovascular event was compared
between the ACS and SA groups and between carriers and non-
carriers among each group for log-rank tests. The cumulative
incidence rates were calculated and expressed as number of
cardiovascular events. Cox regression analysis was used to calculate
the hazard ratio to experience a ﬁrst cardiovascular event according
to the clinical status and CYP2C19 phenotype. Kaplan–Meier curves
were constructed for cumulative event-free survival for the end-
points. Comparisons were expressed as multivariate hazard ratios
and 95% conﬁdence intervals (95% CIs). Signiﬁcant parameters
Table 2
Results of genotyping.
ACS (n = 214) SA (n = 304)
EM (non-carrier) 72 (33.6) 101 (33.2)
IM 102 (47.8) 143 (47.0)
PM 40 (18.7) 60 (19.7)
Carrier (IM + PM) 142 (66.4) 203 (66.7)
Data are number of patients and (percentages). ACS, acute coronary syndrome;
SA, stable angina; EM, extensive metabolizers; subjects carrying normal
function alleles (CYP2C19*1/*1), IM: intermediate metabolizers; subjects
carrying one loss-of-function allele (*1/*2, *1/*3), PM: poor metabolizers;
subjects carrying two loss-of-function alleles (*2/*2, *2/*3, *3/*3).
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Fig. 1. Kaplan–Meier analysis of clinical outcome in ACS and stable angina patients.
Cumulative Kaplan–Meier estimates of rates of cardiovascular events up to 1800
days follow-up period. ACS group showed signiﬁcantly higher cumulative
cardiovascular event rates (20.1%) than SA group (12.5%) (log rank p = 0.015).
ACS, acute coronary syndrome; SA, stable angina.
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likely to have important prognostic value, were entered into a
multivariable, stepwise, forward Cox proportional-hazards model for
association with cardiovascular outcome during 1800 days of follow-
up period. A p-value <0.05 denoted the presence of signiﬁcant
difference. Statistical analysis was performed using Statistical
Package of the Social Science version 21.0 (SPSS Statistics for
Windows, version 21.0. Armonk, NY, USA).
Results
Patient characteristics
The clinical characteristics of each group (ACS and SA) are
summarized in Table 1. Patients with ACS had lower rate of use of
drug-eluting stents, lower ejection fraction, lower prevalence of
diabetes, previous myocardial infarction, and stroke, higher
prevalence of current smoking and higher estimated glomerular
ﬁltration rate, compared to those with SA. The distribution of
CYP2C19 phenotype was 33.6%, 47.8%, and 18.7% in EM, IM, and PM
of the ACS group, and 33.2%, 47.0%, and 19.7% in the EM, IM, and PM
of the SA group, respectively. There was no signiﬁcant difference in
the genotype distribution between the ACS and SA groups
(Table 2). Kaplan–Meier analysis of the ACS and SA groups showed
a signiﬁcantly higher rate of events in the ACS group (log-rank,
p = 0.015) (Fig. 1).
Residual platelet reactivity according to CYP2C19 phenotype in ACS
and SA groups
Residual platelet reactivity measured by ADP-induced platelet
aggregation was signiﬁcantly lower in non-carriers compared with
the carriers in both ACS and SA groups (ACS, non-carriers:
3909  1836 AU min, carriers: 4854  1594 AU min, p < 0.01; SA,
non-carriers: 3606  1579 AU min, carriers: 4381  1373 AU min,
p < 0.01) (Table 3). Furthermore, residual platelet reactivity tended to
be higher in the ACS group compared with the SA group for each
phenotype, although the difference was only statistically signiﬁcant
in carriers (p < 0.01).Table 1
Clinical characteristics.
ACS Stable angina p-value
Number 214 304
Males (n) 150 (70.1) 212 (69.7) 0.931
Age (years) 69.6  11.6 70.1  9.7 0.624
Number of affected vessels
Single 91 (42.5) 118 (38.8) 0.397
Double 72 (33.6) 79 (26.0) 0.059
Triple 31 (14.5) 70 (23.0) 0.016
LMT 20 (9.3) 37 (12.2) 0.312
DES 80 (37.4) 255 (83.9) <0.001
EF 56.7  10.3 59.0  10.3 0.011
BMI (kg/m2) 23.7  3.5 24.0  3.9 0.242
Diabetes 81 (37.9) 168 (55.3) <0.001
Hypertension 146 (68.2) 231 (76.0) 0.051
Dyslipidemia 149 (69.6) 207 (68.1) 0.711
Current smoking 54 (25.4) 39 (12.8) <0.001
Previous MI 18 (8.4) 56 (18.4) 0.001
Previous CABG 5 (2.3) 16 (5.3) 0.096
Previous stroke 20 (9.3) 59 (19.4) 0.002
Fibrinogen 420  124 400  96 0.074
eGFR (mL/min/1.73 m2) 66.4  20.8 58.8  23.2 <0.001
History of GI lesion 37 (17.3) 57 (18.8) 0.659
Data are mean  SD or number of patients (percentage). ACS, acute coronary
syndrome; LMT, left main coronary trunk; DES, drug-eluting stent; EF, ejection
fraction; BMI, body mass index; MI, myocardial infarction; CABG, coronary artery
bypass grafting; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal.Next we compared the drug interaction with proton pump
inhibitors (PPI), and subdivided each group depending on the
usage of PPI. In ACS groups, signiﬁcant difference was found only in
patients with PPI (ACS with PPI, non-carriers: 3852  1963 AU min,
carriers: 4955  1592 AU min, p < 0.05; ACS without PPI, non-
carriers: 4036  1558 AU min, carriers: 4412  1557 AU min,
p = 0.423). However, in SA groups, signiﬁcant difference between
carriers and non-carriers occurred independently of the usage of PPI
(SA with PPI, non-carriers: 3621  1624 AU min, carriers:
4387  1362 AU min, p < 0.05; SA without PPI, non-carriers:Table 3
Residual platelet reactivity according to CYP2C19 phenotype in ACS and SA groups.
ACS Non-carriers
(AU min)
Carriers
(AU min)
p-value
All 3909  1836 4854  1594 <0.01
With PPI 3852  1963 4955  1592 <0.05
Without PPI 4036  1558 4412  1557 0.423
SA Non-carriers
(AU min)
Carriers
(AU min)
p-value
All 3606  1579 4381  1373 <0.01
With PPI 3621  1624 4387  1362 <0.05
Without PPI 3584  1529 4322  1451 <0.05
Data are mean  SD. ACS, acute coronary syndrome; SA, stable angina; PPI, proton
pump inhibitor.
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(Table 3).
Residual platelet reactivity according to carriers and non-carriers of
CYP2C19 loss-of-function alleles
Finally, we assessed the impact of CYP2C19 loss-of-function
allele in each population. ACS and SA patients were divided into
carrier and non-carrier groups based on the presence of CYP2C19
loss-of-function alleles. Patient characteristics were not signiﬁ-
cantly different between carriers and non-carriers (Table 4).
Kaplan–Meier analysis of clinical outcome according to the
presence of CYP2C19 loss-of-function alleles showed signiﬁcant
difference in cardiovascular events in ACS group only (log rank
p = 0.018, Fig. 2A), whereas the difference in the SA group did not
reach statistical signiﬁcance (log rank p = 0.078, Fig. 2B). The
Kaplan–Meier curve for cumulative cardiovascular events showed
a steep increase in the early phase in the ACS group. Landmark
analysis of data from 30 days showed no signiﬁcant difference in
clinical outcome for the ACS group (p = 0.315) (Fig. 3). These results
indicate that the CYP2C19 loss-of-function allele has a signiﬁcant
impact in acute phase ACS.
Multivariable stepwise Cox regression analysis identiﬁed
CYP2C19 carrier state as a signiﬁcant and independent predictor
of cardiovascular events during the follow-up period [hazard ratio
2.1 (95% CI: 1.194–3.587), p = 0.010], in addition to ACS, diabetes
mellitus, previous myocardial infarction, and previous peripheral
arterial disease (Table 5).
Discussion
Several studies have examined the effect of CYP2C19 polymor-
phism in ischemic heart disease [7,8,26]. The results of the presentTable 4
Patient characteristics according to CYP2C19 phenotype for ACS and SA groups.
ACS group 
Carriers Non-carriers 
Number 142 72 
Male 104 (73.2) 46 (63.9) 
Age (years) 70.0  11.4 68.9  11.9 
No. of vessels
Single 58 (40.8) 33 (45.8) 
Double 46 (32.4) 26 (36.1) 
Triple 23 (16.2) 8 (11.1) 
LMT 15 (10.6) 5 (6.9) 
DES 57 (40.1) 23 (31.9) 
EF 57.3  10.1 55.5  10.6 
BMI (kg/m2) 23.7  3.5 23.8  3.4 
Diabetes 55 (38.7) 26 (36.1) 
Hypertension 96 (67.6) 50 (69.4) 
Dyslipidemia 97 (68.3) 52 (72.2) 
Current smoking 39 (27.5) 15 (20.8) 
Previous MI 14 (9.9) 4 (5.6) 
Previous CABG 4 (2.8) 1 (1.4) 
Previous stroke 15 (10.6) 5 (6.9) 
Fibrinogen 410  121 437  130 
eGFR (mL/min/1.73 m2) 65.8  21.0 67.6  20.5 
Previous GI lesion 25 (17.6) 12 (16.6) 
Current medications
Statins 134 (94.4) 63 (87.5) 
b-Blockers 123 (86.6) 66 (91.7) 
Ca-antagonists 75 (52.8) 38 (52.8) 
ACEi/ARB 103 (72.5) 53 (73.6) 
PPI 115 (81.0) 51 (70.8) 
Data are mean  SD or number of patients (percentage). ACS, acute coronary syndrome; S
fraction; BMI, body mass index; MI, myocardial infarction; CABG, coronary artery byp
angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; Pstudy demonstrated differences in the impact of CYP2C19
polymorphism between ACS and SA. The proportion of CYP2C19
phenotype was similar in the two groups. Furthermore, we also
conﬁrmed the results of our previous study [11] of gradual increase
in residual platelet reactivity according to CYP2C19 phenotype in
ACS patients as well as in SA patients. We also demonstrated the
signiﬁcant effect of CYP2C19 loss-of-function allele on clinical
outcome in the ACS group. Furthermore, landmark analysis
demonstrated no signiﬁcant difference in clinical outcome
between carriers and non-carriers of the ACS group from day
30, indicating that the presence of CYP2C19 loss-of-function alleles
had the most powerful effect on the acute phase in ACS.
Our results showed that ACS carriers had the highest residual
platelet reactivity. This ﬁnding is consistent with previous studies
[12,27], which reported that high residual platelet reactivity was a
signiﬁcant negative predictor of adverse clinical outcome. We have
also reported previously that residual platelet reactivity varied
according to the duration of dual antiplatelet therapy [11].
Cardiovascular outcome was signiﬁcantly different between
carriers and non-carriers in ACS patients. Multivariable stepwise
Cox regression analysis also identiﬁed the carrier status as an
independent predictor of cardiovascular events. Our results also
showed that residual platelet reactivity varied according to
CYP2C19 phenotype. Two recent studies targeted residual platelet
reactivity as the regulating factor for carriers of CYP2C19 loss-of-
function alleles [28,29]. Residual platelet reactivity varies accord-
ing to the drugs used and clinical status. Therefore, to understand
the direct relation between CYP2C19 phenotype and residual
platelet reactivity, further studies are needed to measure
coagulability at the time of adverse events.
Kaplan–Meier analysis of data of the SA group showed that the
presence of CYP2C19 loss-of-function alleles did not have a
signiﬁcant impact on clinical outcome in this group. Another groupSA group
p-value Carriers Non-carriers p-value
203 101
0.158 138 (68.0) 74 (73.3) 0.345
0.548 70.3  9.7 69.6  9.6 0.517
0.488 74 (36.5) 44 (43.6) 0.231
0.587 60 (29.6) 19 (18.8) 0.044
0.318 44 (21.7) 26 (25.7) 0.427
0.390 25 (12.3) 12 (11.9) 0.913
0.242 174 (85.7) 81 (80.2) 0.218
0.234 59.2  9.8 58.7  11.2 0.708
0.777 23.7  3.5 24.9  4.5 0.014
0.709 113 (55.7) 55 (54.5) 0.842
0.785 157 (77.3) 74 (73.3) 0.434
0.557 137 (67.5) 70 (69.3) 0.749
0.279 27 (13.3) 12 (11.9) 0.704
0.284 38 (18.7) 18 (17.8) 0.849
0.513 12 (5.9) 4 (4.0) 0.473
0.390 36 (17.7) 23 (22.8) 0.295
0.164 403  90 395  108 0.554
0.547 59.7  23.4 57.1  22.6 0.363
0.864 40 (19.7) 17 (16.8) 0.533
0.079 187 (92.1) 95 (94.1) 0.538
0.277 160 (78.8) 77 (76.2) 0.609
0.996 122 (60.1) 58 (57.4) 0.655
0.867 142 (70.0) 70 (69.3) 0.908
0.092 130 (64.0) 59 (59.4) 0.341
A, stable angina; LMT, left main coronary trunk; DES, drug-eluting stent; EF, ejection
ass grafting; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; ACEi,
PI, proton pump inhibitor.
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Fig. 2. Kaplan–Meier analysis of cumulative cardiovascular event rate based on
CYP2C19 loss-of-function allele in patients with ACS and SA. Cumulative Kaplan–
Meier estimates of rates of cardiovascular events up to 1800 days follow-up period
according to CYP2C19 loss-of-function allele carriers and non-carriers. The
cumulative cardiovascular event rate was signiﬁcantly higher in carriers than in
non-carriers among the ACS group (log rank p = 0.018). Among SA groups, a higher
event rate was also noted, but the difference between carriers and non-carriers was
not signiﬁcant (log rank p = 0.078). ACS, acute coronary syndrome; SA, stable
angina.
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Fig. 3. Landmark analysis from day 30 based on CYP2C19 loss-of-function allele in
patients with ACS. There was no signiﬁcant difference between carriers and non-
carriers (log rank p = 0.315). ACS, acute coronary syndrome.
Table 5
Results of multivariate Cox proportional hazard analysis of cardiovascular events
using data of the entire group.
p-value HR 95% CI
Acute coronary syndrome 0.003 2.000 1.269–3.150
Diabetes mellitus 0.024 1.700 1.072–2.693
Previous myocardial infarction 0.038 1.778 1.033–3.061
Previous peripheral arterial disease 0.041 1.922 1.028–3.594
CYP2C19 carrier 0.010 2.069 1.194–3.587
HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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impact on the long-term prognosis of patients with coronary artery
disease [27]. This report only analyzed CYP2C19*2 carriers, but
targeted Asian population similar to the present study, so
proportional difference of CYP2C19 genotype to Caucasian might
inﬂuence different clinical outcomes depending on the ethnicity.
Our data also included CYP2C19*3 loss-of-function allele, so
further analysis about long-term prognosis would be required. The
hypercoagulation status in ACS is modulated by various factors
[30,31], and residual platelet reactivity is one of the major
modulators, but the effects of other factors cannot be ignored. Our
ﬁndings suggest the presence of augmented hypercoagulation
state in CYP2C19 loss-of-function carriers especially those of the
ACS group. In addition to cytochrome P450, CYP2C19 serves
various functions in addition to drug metabolism [32]. One
previous study reported its relation to cardiovascular disease
[33], and thus the effect of CYP2C19 loss-of-function allele in
carriers, other than those on drug metabolism, might be relatedto the pathophysiology of cardiovascular disease. Further studies
of a larger number of patients are needed to examine the direct
effect of residual platelet reactivity on the risk of clinical
cardiovascular events in CYP2C19 loss-of-function carriers in
Japanese patients.
Study limitations
The present study has certain limitations that need to be taken
into account before full interpretation of the results. (1) The study
was performed in a single center. (2) Compared to previous studies
in Western countries, the number of study patients was small,
which could explain the lack of differences in clinical event rates
between the groups. (3) In this study, we calculated platelet
reactivity in the peri-procedural period, and accordingly we do not
know whether high residual platelet reactivity existed at the time
of cardiovascular events. (4) We did not measure plasma levels of
the active metabolite of clopidogrel, and therefore we cannot
provide direct evidence of reduced antiplatelet efﬁcacy of
clopidogrel in patients carrying at least one CYP2C19*2 or *3
alleles. Thus, the results of the present study may be incomplete
due to the lack of data on clopidogrel metabolism. (5) Although
several factors could explain the increased risk for cardiovascular
events under clopidogrel treatment, we focused on CYP2C19
polymorphism in this study. The results demonstrated that carrier
status with at least one CYP2C19 loss-of-function allele is
associated with increased platelet reactivity and increased risk
for cardiovascular events following stent implantation irrespective
of the metabolizer state (PM or IM). Further studies are needed to
elucidate the difference in clinical outcome between PM and IM.
Y. Arima et al. / Journal of Cardiology 65 (2015) 494–500 499(6) The results do not exclude the effects of drug-metabolizing
enzymes other than CYP2C19, such as CYP1A2, 2B6, 3A, and 2C9, on
clopidogrel response. (7) One cannot rule out the possibility that
CYP2C19 polymorphism directly affects atherothrombotic cardio-
vascular events, rather than through modulation of the clopidogrel
response. (8) Finally, the study patients were being treated with
various medications at the time of the study. Such medications
could alter the effects of genetic factors on the response to
clopidogrel.
Conclusions
CYP2C19 genotype is a key risk factor for cardiovascular events
following stent implantation in Japanese patients. Residual platelet
reactivity was higher in carriers of CYP2C19 loss-of-function alleles
compared with non-carriers. The rate of cardiovascular events was
higher in CYP2C19 loss-of-function carriers than non-carriers
among ACS patients, especially during the acute phase.
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